Announcements - OBI Pharma

2025.Dec.19

The Company’s BOD resolved to enter into commercial licensing agreement with TegMine for the development of glycoprotein monoclonal antibody ADC

2025.Dec.19

Announcement of BOD’s resolution to lift the non-competition restrictions for managerial officer

2025.Dec.19

Announcement pursuant to Article 22.1(3) of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

2025.Dec.17

Announcement on behalf of Amaran that its BOD has elected Dr. Heidi Wang to serve as Chairperson of the Board and concurrently as General Manager

2025.Dec.09

Announcement on behalf of Amaran the resignation of director

2025.Dec.09

Announcement on behalf of Amaran the retirement of Chairperson of the Board and General Manager

2025.Dec.05

OBI receives US FDA Orphan Drug Designation for OBI-902 TROP2 ADC for the treatment of gastric cancer

2025.Nov.24

Announcement of the Company’s record date of capital reduction, record date of share replacement, and related operational plan

2025.Nov.16

OBI receives US FDA Orphan Drug Designation for OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma

2025.Nov.14

OBI is invited to present the current development status of its products and technology platforms at the investor conference hosted by MasterLink

News

Latest News

Events

Latest events